How much did Ingevity repurchase in Q2 2026 and at what price?

The company repurchased approximately $35 million in shares during Q2 2026 at a weighted average cost per share of $70.94. This activity reduced share count while the company generated strong free cash flow of $89.1 million (excluding the one-time litigation settlement).

How much authorization remains for future buybacks?

Approximately $211 million of authorization remains available under the current repurchase program. Management indicated the company intends to utilize strong free cash flow both to reduce leverage and return cash to shareholders through buybacks.

What is Ingevity's stated capital allocation priority?

The company prioritizes reducing net leverage to its long-term target range of 2.0–2.5 times, while also returning cash to shareholders through buybacks and dividends. As of Q2 2026, net leverage stood at 2.5x, down from 3.0x a year earlier.

What is the expected free cash flow for full-year 2026?

The company expects full-year 2026 free cash flow between $220 million and $245 million, excluding $113.2 million in litigation settlement payments. This robust cash generation supports both deleveraging and shareholder returns.

Did the Road Markings divestiture affect the buyback program?

The April 2026 divestiture of the Road Markings product line generated approximately $63 million in net proceeds, contributing to improved liquidity. Management stated the divestiture demonstrates commitment to portfolio transformation and creating a stronger foundation for long-term shareholder value.

How has Ingevity's operational performance supported the buybacks?

Q2 2026 adjusted EBITDA grew 14% to $115.0 million with margin expansion to 36.6%, compared to 30.5% in the prior year. Strong commercial execution across all three business segments and improved asset utilization have bolstered cash generation and supported the company's ability to execute buybacks while deleveraging.

NGVT 8-K Filed 2026-07-29 Execution disclosure

Ingevity repurchased $35M shares in Q2 2026 at $70.94 average

Specialty materials company executed $35M in buybacks; $211M remains under authorization

Avg price paid$70.94

Remaining$211M

MechanismRule 10b-18 open-market purcha

What the filing says

Ingevity Corporation (NYSE: NGVT) repurchased approximately $35 million in shares during the second quarter of 2026 at a weighted average cost per share of $70.94, according to the company's Q2 earnings report filed with the SEC on July 29, 2026. The buyback was executed under the company's existing share repurchase authorization.

Following the repurchase activity, approximately $211 million remained available capacity under the current authorization, providing the company flexibility for future buybacks. Ingevity generated strong free cash flow of $89.1 million in Q2 2026 (excluding a one-time $113.2 million litigation settlement payment) and expects full-year free cash flow between $220 million and $245 million, excluding the litigation settlement.

Management stated in the filing that the company "intends to utilize the strong free cash flow to reduce leverage to within our long-term target range of 2.0 to 2.5 times and return cash to shareholders." The company achieved a net debt ratio of 2.5x as of June 30, 2026, down from 3.0x in the prior-year quarter, reflecting both the buyback activity and debt reduction efforts.

Share repurchases totaled approximately $35 million for the second quarter at a weighted average cost per share of $70.94, with approximately $211 million available capacity remaining under the company's current share repurchase authorization. — Ingevity Corp 8-K filing · View on SEC EDGAR →

What this means

Ingevity's Q2 repurchase of $35 million represents continued capital allocation to shareholders while the company simultaneously deleverages. The execution at $70.94 per share comes amid improved operational performance, with adjusted EBITDA margin expanding to 36.6% from 30.5% year-over-year. With $211 million in remaining authorization and robust free-cash-flow generation, the company has substantial firepower for future buybacks, though management has explicitly stated priority is reducing net leverage to the 2.0–2.5x target range. The buyback activity reflects confidence in the business following portfolio optimization actions, including the April 2026 divestiture of the Road Markings product line.

Frequently asked questions

How much did Ingevity repurchase in Q2 2026 and at what price?: The company repurchased approximately $35 million in shares during Q2 2026 at a weighted average cost per share of $70.94. This activity reduced share count while the company generated strong free cash flow of $89.1 million (excluding the one-time litigation settlement).
How much authorization remains for future buybacks?: Approximately $211 million of authorization remains available under the current repurchase program. Management indicated the company intends to utilize strong free cash flow both to reduce leverage and return cash to shareholders through buybacks.
What is Ingevity's stated capital allocation priority?: The company prioritizes reducing net leverage to its long-term target range of 2.0–2.5 times, while also returning cash to shareholders through buybacks and dividends. As of Q2 2026, net leverage stood at 2.5x, down from 3.0x a year earlier.
What is the expected free cash flow for full-year 2026?: The company expects full-year 2026 free cash flow between $220 million and $245 million, excluding $113.2 million in litigation settlement payments. This robust cash generation supports both deleveraging and shareholder returns.
Did the Road Markings divestiture affect the buyback program?: The April 2026 divestiture of the Road Markings product line generated approximately $63 million in net proceeds, contributing to improved liquidity. Management stated the divestiture demonstrates commitment to portfolio transformation and creating a stronger foundation for long-term shareholder value.
How has Ingevity's operational performance supported the buybacks?: Q2 2026 adjusted EBITDA grew 14% to $115.0 million with margin expansion to 36.6%, compared to 30.5% in the prior year. Strong commercial execution across all three business segments and improved asset utilization have bolstered cash generation and supported the company's ability to execute buybacks while deleveraging.

execution mid-cap specialty-materials rule-10b-18 Q2-2026 capital-allocation

Source. This editorial summary is based on the SEC filing linked above. BuybackStocks aggregates and editorializes publicly available SEC EDGAR filings. Not investment advice. Past authorization announcements do not guarantee future repurchase activity or share price performance. See our full disclosures policy.